The C5a complement activation peptide increases IL-1beta and IL-6 release from amyloid-beta primed human monocytes: implications for Alzheimer's disease

J Neuroimmunol. 2000 Sep 22;109(2):87-94. doi: 10.1016/s0165-5728(00)00291-5.

Abstract

Alzheimer's disease (AD) brains contain large numbers of amyloid-beta peptide (Abeta) deposits associated with activated microglia, astrocytes and dystrophic neurites. Activated complement components and pro-inflammatory cytokines are also present, indicative of focal inflammation. However, neither Abeta, nor the chemokine-like mediator, C5a, which is generated by Abeta-mediated complement activation, significantly activates microglia, as assessed by pro-inflammatory cytokine release. We evaluated the possibility that both together would co-stimulate such release using the THP-1 human monocytic cell line as a microglial surrogate, and found this to be the case. These studies support the hypothesis that Abeta and C5a induce a chronic microglia-mediated focal inflammatory response in AD.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Alzheimer Disease / immunology*
  • Alzheimer Disease / metabolism
  • Amyloid beta-Peptides / immunology
  • Amyloid beta-Peptides / pharmacology*
  • Cell Line
  • Complement Activation / drug effects
  • Complement Activation / immunology
  • Complement C5a / immunology
  • Complement C5a / pharmacology*
  • Gene Expression / immunology
  • Humans
  • Inflammation / immunology
  • Inflammation / metabolism
  • Interleukin-1 / metabolism*
  • Interleukin-6 / metabolism*
  • Microglia / immunology
  • Monocytes / cytology
  • Monocytes / drug effects
  • Monocytes / metabolism*
  • NF-kappa B / genetics
  • NF-kappa B / immunology
  • Transcription, Genetic / immunology

Substances

  • Amyloid beta-Peptides
  • Interleukin-1
  • Interleukin-6
  • NF-kappa B
  • Complement C5a